VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ELUTElutia Inc.
$1.06$47M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

ELUT logoElutia Inc.(ELUT)Earnings, Financials & Key Ratios

ELUT•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryRegenerative Medicine and Tissue Engineering
AboutElutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Show more
  • Revenue$12M-49.6%
  • EBITDA-$16M+51.5%
  • Net Income$53M+198.9%
  • EPS (Diluted)-0.79+57.5%
  • Gross Margin53.66%+22.2%
  • EBITDA Margin-127.12%+3.8%
  • Operating Margin-149.78%-2.4%
  • Net Margin434.23%+296.2%
  • ROE192.9%

ELUT Key Insights

Elutia Inc. (ELUT) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Excellent 3Y average ROE of 192.9%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Sales declining 22.0% over 5 years
  • ✗Shares diluted 58.0% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when ELUT posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ELUT Price & Volume

Elutia Inc. (ELUT) stock price & volume — 10-year historical chart

Loading chart...

ELUT Growth Metrics

Elutia Inc. (ELUT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-22.04%
3 Years-19.82%
TTM-32.64%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM224.96%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM144.56%

Return on Capital

10 Years-81.32%
5 Years-121.2%
3 Years-166.49%
Last Year-103.6%

ELUT Peer Comparison

Elutia Inc. (ELUT) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
NVCR logoNVCRNovoCure LimitedDirect Competitor1.62B14.28-11.708.28%-25.66%-50.82%0.85
XTNT logoXTNTXtant Medical Holdings, Inc.Direct Competitor61.8M0.4414.6914.21%1.5%3.68%0.56
OSBC logoOSBCOld Second Bancorp, Inc.Direct Competitor1.15B21.8913.5118.09%20.23%10.11%0.38
LMAT logoLMATLeMaitre Vascular, Inc.Direct Competitor2.14B93.9537.2813.53%24.35%16.19%0.47
MDT logoMDTMedtronic plcProduct Competitor101.86B79.3421.983.62%13%9.49%0.59
ABT logoABTAbbott LaboratoriesProduct Competitor153.68B88.3811.574.59%31.88%27.26%0.32
BSX logoBSXBoston Scientific CorporationProduct Competitor67.31B45.2923.3519.87%14.4%12.4%0.51
SYK logoSYKStryker CorporationProduct Competitor117.88B307.8036.6411.16%12.92%15.04%0.66

Compare ELUT vs Peers

Elutia Inc. (ELUT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NVCR

Most directly comparable listed peer for ELUT.

Scale Benchmark

vs ABT

Larger-name benchmark to compare ELUT against a more recognizable public peer.

Peer Set

Compare Top 5

vs NVCR, XTNT, OSBC, LMAT

ELUT Income Statement

Elutia Inc. (ELUT) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
39.04M42.9M42.68M47.39M23.85M24.75M24.38M12.29M15.97M
Revenue Growth %
-9.9%-0.51%11.03%-49.68%3.76%-1.5%-49.57%-32.64%
Cost of Goods Sold
23.09M23.13M22.12M28.37M12.21M13.69M13.67M5.7M7.34M
COGS % of Revenue
59.16%53.92%51.83%59.86%51.2%55.33%56.07%46.34%-
Gross Profit
15.95M▲ 0%
19.77M▲ 24.0%
20.56M▲ 4.0%
19.02M▼ 7.5%
11.64M▼ 38.8%
11.05M▼ 5.0%
10.71M▼ 3.1%
6.6M▼ 38.4%
8.63M▲ 0%
Gross Margin %
40.84%46.08%48.17%40.14%48.8%44.67%43.93%53.66%54.02%
Gross Profit Growth %
-23.98%4.01%-7.49%-38.81%-5.03%-3.13%-38.4%-
Operating Expenses
24.17M28.18M34.16M42.05M46.83M41.58M46.36M25.01M34.09M
OpEx % of Revenue
61.9%65.68%80.03%88.74%196.35%168.03%190.19%203.43%-
Selling, General & Admin
21.68M25.78M28.21M32.51M33.9M27.19M31.2M20.84M19.51M
SG&A % of Revenue
55.55%60.08%66.08%68.61%142.15%109.88%128.02%169.57%-
Research & Development
2.48M2.4M5.95M9.27M7.73M4.4M3.79M4.16M5.73M
R&D % of Revenue
6.36%5.59%13.95%19.55%32.4%17.78%15.53%33.86%-
Other Operating Expenses
000276K5.2M9.99M11.37M02M
Operating Income
-8.22M▲ 0%
-8.41M▼ 2.3%
-13.6M▼ 61.7%
-23.03M▼ 69.4%
-35.19M▼ 52.8%
-30.53M▲ 13.3%
-35.65M▼ 16.8%
-18.41M▲ 48.4%
-25.46M▲ 0%
Operating Margin %
-21.06%-19.6%-31.86%-48.6%-147.55%-123.36%-146.26%-149.78%-159.43%
Operating Income Growth %
--2.29%-61.72%-69.37%-52.78%13.25%-16.79%48.35%-
EBITDA
-4.42M-4.55M-9.73M-19.3M-31.46M-27.02M-32.2M-15.63M-23.22M
EBITDA Margin %
-11.32%-10.61%-22.81%-40.73%-131.9%-109.18%-132.1%-127.12%-145.36%
EBITDA Growth %
--2.99%-113.82%-98.27%-62.97%14.11%-19.18%51.47%26.62%
D&A (Non-Cash Add-back)
3.8M3.86M3.86M3.73M3.73M3.51M3.45M2.79M2.25M
EBIT
-6.02M-6.53M-16.17M-19.45M-31.03M-35.42M-49.34M-18.41M-20.43M
Net Interest Income
-5.52M-5.38M-5.63M-5.32M-5.12M-5.8M-4.78M387K2.96M
Interest Income
000000000
Interest Expense
5.52M5.38M5.63M5.32M5.12M5.8M4.78M-387K-2.96M
Other Income/Expense
-3.32M-3.5M-8.2M-1.75M-959K-10.7M-18.47M2.55M1.14M
Pretax Income
-11.54M▲ 0%
-11.91M▼ 3.2%
-21.8M▼ 83.0%
-24.78M▼ 13.7%
-36.15M▼ 45.9%
-41.22M▼ 14.0%
-54.12M▼ 31.3%
-15.86M▲ 70.7%
-24.32M▲ 0%
Pretax Margin %
-29.56%-27.76%-51.07%-52.28%-151.57%-166.58%-222.04%-129%-152.29%
Income Tax
26K30K26K55K34K28K7K13K75K
Effective Tax Rate %
-0.23%-0.25%-0.12%-0.22%-0.09%-0.07%-0.01%-0.08%-0.31%
Net Income
-11.57M▲ 0%
-11.94M▼ 3.2%
-21.82M▼ 82.8%
-24.83M▼ 13.8%
-32.9M▼ 32.5%
-37.66M▼ 14.5%
-53.95M▼ 43.3%
53.38M▲ 198.9%
49.84M▲ 0%
Net Margin %
-29.63%-27.83%-51.13%-52.4%-137.94%-152.18%-221.33%434.23%312.09%
Net Income Growth %
--3.23%-82.8%-13.78%-32.48%-14.47%-43.27%198.95%224.96%
Net Income (Continuing)
-11.57M-11.94M-21.82M-24.83M-36.18M-41.25M-54.13M-15.87M-24.4M
Discontinued Operations
00003.29M3.59M180K69.25M425K
Minority Interest
000000000
EPS (Diluted)
-1.08▲ 0%
-1.12▼ 3.7%
-2.13▼ 90.2%
-2.38▼ 11.7%
-2.38▲ 0.0%
-2.07▲ 13.0%
-1.86▲ 10.1%
-0.79▲ 57.5%
1.16▲ 0%
EPS Growth %
--3.7%-90.18%-11.74%0%13.03%10.14%57.53%144.56%
EPS (Basic)
-1.08-1.12-2.13-2.38-2.38-2.07-1.861.29-
Diluted Shares Outstanding
10.67M10.67M10.23M10.44M13.83M18.16M29.07M45.94M43M
Basic Shares Outstanding
10.67M10.67M10.23M10.44M13.83M18.16M29.07M41.42M43M
Dividend Payout Ratio
---------

ELUT Balance Sheet

Elutia Inc. (ELUT) balance sheet — assets, liabilities & shareholders' equity

MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
18.14M18.45M59.71M47.43M50.7M31.25M26.17M55.82M48.59M
Cash & Short-Term Investments
2.41M2.48M39.15M30.39M16.99M19.28M13.24M36.35M28.49M
Cash Only
2.41M2.48M39.15M30.39M16.99M19.28M13.24M36.35M28.49M
Short-Term Investments
000000000
Accounts Receivable
7.2M7.23M7.17M6M17.59M5.96M7.04M6.58M2.07M
Days Sales Outstanding
67.3261.561.2846.18269.1687.9105.36195.37157.97
Inventory
7.46M7.19M10.12M9.55M4.24M3.85M3.91M2.62M2.66M
Days Inventory Outstanding
117.89113.45166.93122.93126.75102.71104.44167.67155.66
Other Current Assets
46K108K382K35K11.88M2.17M1.99M10.27M15.38M
Total Non-Current Assets
29.61M26.33M23.1M19.74M18.14M12.18M9.96M6.53M6.62M
Property, Plant & Equipment
870K988K1.16M1.2M565K504K1.68M5M5.36M
Fixed Asset Turnover
44.87x43.42x36.73x39.49x42.21x49.10x14.49x2.46x3.20x
Goodwill
000000000
Intangible Assets
025.26M21.86M18.47M15.07M11.67M8.27M1.53M1.26M
Long-Term Investments
000000000
Other Non-Current Assets
28.74M76K76K76K2.51M0000
Total Assets
47.74M▲ 0%
44.77M▼ 6.2%
82.81M▲ 85.0%
67.17M▼ 18.9%
68.84M▲ 2.5%
43.43M▼ 36.9%
36.13M▼ 16.8%
62.35M▲ 72.6%
55.21M▲ 0%
Asset Turnover
0.82x0.96x0.52x0.71x0.35x0.57x0.67x0.20x0.35x
Asset Growth %
--6.22%84.96%-18.89%2.49%-36.92%-16.81%72.59%54.6%
Total Current Liabilities
13.35M18.27M26.78M26M42.62M43.04M37.8M25.14M23.73M
Accounts Payable
1.59M2.49M2.05M1.58M1.37M3.19M4.15M9.14M9.69M
Days Payables Outstanding
25.1239.3233.8920.3641.0785.07110.8585.78427.7
Short-Term Debt
6.46M5.92M12.82M12.82M03.32M1.71M4.75M524K
Deferred Revenue (Current)
0650K533K5K00000
Other Current Liabilities
-1.26M2.75M2.75M2.75M31.28M26.77M24.83M11.24M13.52M
Current Ratio
1.36x1.01x2.23x1.82x1.19x0.73x0.69x2.22x2.05x
Quick Ratio
0.80x0.62x1.85x1.46x1.09x0.64x0.59x2.12x1.94x
Cash Conversion Cycle
160.1135.63194.32148.75354.84105.5599-222.74-114.07
Total Non-Current Liabilities
77.8M81.61M35.2M27.65M31.26M38.99M44.59M9.54M8.96M
Long-Term Debt
75.92M19.61M17.81M10.41M24.26M20.36M22.6M2.83M5.57M
Capital Lease Obligations
0000956K0423K06.3M
Deferred Tax Liabilities
000000000
Other Non-Current Liabilities
1.88M61.29M16.63M16.54M6.04M18.64M21.57M6.71M3.39M
Total Liabilities
91.15M99.88M61.98M53.65M73.87M82.03M82.39M34.68M32.68M
Total Debt
82.39M25.53M30.64M23.24M25.45M23.95M24.74M7.58M6.09M
Net Debt
79.97M23.05M-8.52M-7.16M8.46M4.68M11.5M-28.77M-22.4M
Debt / Equity
--1.47x1.72x---0.27x0.27x
Debt / EBITDA
---------0.26x
Net Debt / EBITDA
--------0.96x
Interest Coverage
-1.09x-1.21x-2.87x-3.65x-6.06x-6.11x-10.32x-47.58x6.90x
Total Equity
-43.41M▲ 0%
-55.11M▼ 27.0%
20.83M▲ 137.8%
13.52M▼ 35.1%
-5.03M▼ 137.2%
-38.6M▼ 666.9%
-46.26M▼ 19.8%
27.67M▲ 159.8%
22.53M▲ 0%
Equity Growth %
--26.97%137.8%-35.09%-137.22%-666.94%-19.84%159.82%347.43%
Book Value per Share
-4.07-5.172.041.29-0.36-2.13-1.590.600.52
Total Shareholders' Equity
-43.41M-55.11M20.83M13.52M-5.03M-38.6M-46.26M27.67M22.53M
Common Stock
9K1K10K13K16K23K35K43K44K
Retained Earnings
-45M-56.94M-80.26M-105.09M-137.99M-175.64M-229.59M-176.21M-183.68M
Treasury Stock
000000000
Accumulated OCI
0-56.94M-80.26M000000
Minority Interest
000000000

ELUT Cash Flow Statement

Elutia Inc. (ELUT) cash flow — operating, investing & free cash flow history

MetricDec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
-5.13M-7.22M-13.63M-15.45M-21.43M-21.76M-22.66M-44.81M-43.76M
Operating CF Margin %
-13.13%-16.84%-31.92%-32.59%-89.87%-87.94%-92.95%-364.52%-
Operating CF Growth %
--40.98%-88.6%-13.36%-38.77%-1.53%-4.12%-97.78%-164.8%
Net Income
-11.57M-11.94M-21.82M-24.83M-32.9M-37.66M-53.95M53.38M49.84M
Depreciation & Amortization
3.8M3.86M3.86M3.73M3.73M3.73M3.67M1.17M1.85M
Stock-Based Compensation
0208K779K3.54M3.65M2.44M7.89M4.4M2.95M
Deferred Taxes
000000013K0
Other Non-Cash Items
9.02M1.12M6.22M-254K-1.63M661K15.64M-85.04M-84.09M
Working Capital Changes
1.38M-467K-2.67M2.38M5.71M9.07M4.09M-18.73M-18.18M
Change in Receivables
-1.61M-30K64K1.17M-14.65M802K527K-2K-717K
Change in Inventory
1.1M269K-2.93M563K-498K-609K-58K-1.64M-1.31M
Change in Payables
352K-627K00000-6.55M2.83M
Cash from Investing
-190K-577K-640K-369K-540K14.21M-474K78.56M78.8M
Capital Expenditures
-190K-577K-640K-369K-540K-346K-654K-1.88M-2.06M
CapEx % of Revenue
0.49%1.34%1.5%0.78%2.26%1.4%2.68%15.26%12.88%
Acquisitions
000000080.44M80.86M
Investments
---------
Other Investing
0000014.55M180K00
Cash from Financing
6.99M7.98M51.21M6.71M8.54M9.84M17.09M-10.64M-23.91M
Debt Issued (Net)
-3.96M6.73M6.98M-4.53M1.62M-1.96M-2M-23.06M-23.06M
Equity Issued (Net)
442K2.28M46.47M13.75M10.09M-32K-1.19M13.91M-19K
Dividends Paid
000000000
Share Repurchases
00000-32K-1.19M0-97K
Other Financing
10.51M-1.03M-2.24M-2.51M-3.18M11.83M20.28M-1.48M-830K
Net Change in Cash
1.67M▲ 0%
177K▼ 89.4%
36.94M▲ 20771.2%
-9.1M▼ 124.6%
-13.44M▼ 47.6%
2.29M▲ 117.0%
-6.04M▼ 364.0%
23.11M▲ 482.8%
11.13M▲ 0%
Free Cash Flow
-5.32M▲ 0%
-7.8M▼ 46.8%
-14.27M▼ 82.9%
-15.81M▼ 10.9%
-21.97M▼ 38.9%
-22.11M▼ 0.6%
-23.31M▼ 5.4%
-46.69M▼ 100.3%
-45.82M▲ 0%
FCF Margin %
-13.61%-18.19%-33.42%-33.37%-92.14%-89.34%-95.63%-379.78%-286.88%
FCF Growth %
--46.79%-82.85%-10.86%-38.94%-0.61%-5.45%-100.27%-53.68%
FCF per Share
-0.50-0.73-1.40-1.51-1.59-1.22-0.80-1.02-1.07
FCF Conversion (FCF/Net Income)
0.44x0.61x0.62x0.62x0.65x0.58x0.42x-0.84x-0.92x
Interest Paid
3.47M4.4M5.11M4.98M5.48M2.32M12.69M022K
Taxes Paid
16K25K32K000000

ELUT Key Ratios

Elutia Inc. (ELUT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2019202020212022202320242025TTM
Return on Equity (ROE)
--104.77%-144.57%-775.14%--192.9%-560.64%
Return on Invested Capital (ROIC)
-280.05%-82.81%-184.94%-539.1%---155.83%
Gross Margin
46.08%48.17%40.14%48.8%44.67%43.93%53.66%54.02%
Net Margin
-27.83%-51.13%-52.4%-137.94%-152.18%-221.33%434.23%312.09%
Debt / Equity
-1.47x1.72x---0.27x0.27x
Interest Coverage
-1.21x-2.87x-3.65x-6.06x-6.11x-10.32x-47.58x6.90x
FCF Conversion
0.61x0.62x0.62x0.65x0.58x0.42x-0.84x-0.92x
Revenue Growth
9.9%-0.51%11.03%-49.68%3.76%-1.5%-49.57%-32.64%
Related:ELUT Dividend History·ELUT Revenue History·ELUT Price History·ELUT P/E History·ELUT Financial Ratios·ELUT Institutional Holders

ELUT SEC Filings & Documents

Elutia Inc. (ELUT) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 14, 2026·SEC

Material company update

Mar 11, 2026·SEC

Material company update

Mar 9, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 13, 2026·SEC

FY 2025

Mar 11, 2025·SEC

FY 2024

Mar 11, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 15, 2026·SEC

FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 14, 2025·SEC

ELUT Frequently Asked Questions

Elutia Inc. (ELUT) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Elutia Inc. (ELUT) reported $16.0M in revenue for fiscal year 2025. This represents a 59% decrease from $39.0M in 2018.

Elutia Inc. (ELUT) saw revenue decline by 49.6% over the past year.

Yes, Elutia Inc. (ELUT) is profitable, generating $49.8M in net income for fiscal year 2025 (434.2% net margin).

Dividend & Returns

Elutia Inc. (ELUT) has a return on equity (ROE) of 192.9%. This is excellent, indicating efficient use of shareholder capital.

Elutia Inc. (ELUT) had negative free cash flow of $45.8M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in ELUT back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →

How much would $100/month in ELUT be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →